ANGLE plc signs deal with AstraZeneca to develop Parsortix-based AR detection assay for prostate cancer studies
In a deal valued at £550,000, ANGLE plc (AIM:AGL, OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumor cell (CTC) solutions, has secured an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop a Parsortix-based Androgen Receptor (AR) detection assay for prostate cancer studies. The assay will be developed in ANGLE’s UK laboratories, and its successful […]